Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast by Perez, Amanda Arantes et al.
Immunohistochemical profile of high-grade ductal
carcinoma in situ of the breast
Amanda Arantes Perez,I Rafael Malagoli Rocha,II De´bora Balabram,I A´tila da Silva Souza,I Helenice GobbiI
I Faculdade de Medicina da Universidade Federal de Minas Gerais, Breast Pathology Laboratory, Belo Horizonte/MG, Brazil. IIA.C. Camargo Cancer
Hospital, Sa˜o Paulo/SP, Brazil.
OBJECTIVE: To determine the frequency of the immunohistochemical profiles of a series of high-grade ductal
carcinoma in situ of the breast.
METHODS: One hundred and twenty-one cases of high-grade ductal carcinoma in situ, pure or associated with
invasive mammary carcinoma, were identified from 2003 to 2008 and examined with immunohistochemistry for
estrogen receptor, human epidermal growth factor receptor 2, cytokeratin 5, and epidermal growth factor
receptor. The tumors were placed into five subgroups: luminal A, luminal B, HER2, basal-like, and ‘‘not
classified’’.
RESULTS: The frequencies of the immunophenotypes of pure ductal carcinoma in situ were the following:
luminal A (24/42 cases; 57.1%), luminal B (05/42 cases; 11.9%), HER2 (07/42 cases; 16.7%), basal-like phenotype
(00/42 cases; 0%), and ‘‘not classified’’ (06/42 cases; 14.3%). The immunophenotypes of ductal carcinoma in situ
associated with invasive carcinoma were the following: luminal A (46/79 cases; 58.2%), luminal B (10/79 cases;
12.7%), HER2 (06/79 cases; 7.6%), basal-like (06/79 cases; 7.6%), and ‘‘not classified’’ (11/79 cases; 13.9%). There
was no significant difference in the immunophenotype frequencies between pure ductal carcinoma in situ and
ductal carcinoma in situ associated with invasive carcinoma (p.0.05). High agreement was observed in
immunophenotypes between both components (kappa=0.867).
CONCLUSION: The most common immunophenotype of pure ductal carcinoma in situ was luminal A, followed
by HER2. The basal-like phenotype was observed only in ductal carcinoma in situ associated with invasive
carcinoma, which had a similar phenotype.
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& INTRODUCTION
Breast cancer has a heterogeneous natural history and
varying morphological and immunohistochemical profiles
and prognoses. Until recently, the classification and
therapeutic decisions regarding breast carcinoma were
based on histological features and classical prognostic and
predictive factors.
Recent cDNA microarray studies have identified distinct
groups of tumors with disparate prognoses, resulting in a
new classification of invasive breast carcinomas. Breast
tumors are categorized into five subgroups based on their
molecular profile: luminal A, luminal B, HER2, basal-like,
and normal breast-like (1–3). Gene expression signatures
and protein expression profiles through immunohistochem-
istry correlate well in invasive breast cancers (4–8).
The basal-like subtype has attracted the attention of
researchers and physicians because it has been associated
with poor clinical outcomes. These outcomes likely reflect
this subtype’s high proliferative capacity and the lack of
directed therapies, as basal-like tumors do not typically
express estrogen receptor or overexpress HER2 (2–3). The
basal-like phenotype is more frequent among invasive
tumors that have a high histological grade (9–11).
Ductal carcinoma in situ (DCIS) represents a precursor
lesion to invasive breast cancer, in which most molecular
alterations are already present (12). Based on this model,
basal-like invasive ductal carcinomas, which are primarily
high grade, arise from high-grade DCIS.
Many studies have evaluated invasive mammary carci-
nomas (IMCs), but few studies have examined the
molecular profile of DCIS of the breast through immuno-
histochemistry. Assuming that DCIS is a precursor of
invasive carcinoma, we expect that the molecular phenotypes
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previously described for IMC will also be identified among
cases of DCIS.
The purpose of this study was to determine the frequency
of the basal-like phenotype and other immunophenotypes
in a series of cases of high-grade DCIS of the breast, either
pure or associated with invasive carcinoma, to compare the
frequency of immunohistochemical profiles in pure or IMC-
associated DCIS cases and to assess the agreement of
immunophenotypes between in situ and invasive compo-
nents in DCIS cases that are associated with invasive
components. We chose a specific subset of high-grade
DCIS because the basal-like phenotype is more frequent
among invasive tumors that have a high histological grade
(9–11). By identifying basal-like DCIS, these tumors can be
treated more aggressively than other DCIS subtypes to
improve the prognosis.
& MATERIALS AND METHODS
Specimen selection
In total, 202 cases of high-grade DCIS, pure or associated
with invasive carcinoma, were consecutively identified from
the histopathology files of the Breast Pathology Laboratory,
School of Medicine, Federal University of Minas Gerais,
Brazil, from 2003 to 2008. Seventy-one cases (35%) were
excluded: 14 cases showed autolysis (7%), 32 cases received
neoadjuvant chemotherapy (16%), 11 cases were a local
recurrence following breast-conserving surgery (5%), and 14
cases had insufficient tumor tissue for sectioning (7%). The
original hematoxylin and eosin-stained sections from 131
cases were reviewed to confirm the diagnosis of high-grade
DCIS and select a representative block for immunostaining.
Formalin-fixed, paraffin-embedded blocks were not found
in 10 cases (5% of the total). Thus, immunohistochemistry
was performed in 121 high-grade DCIS cases (60% of the
total).
The criteria defined by the World Health Organization
(2012) were used for the histopathological diagnosis of DCIS
(13). The DCIS histological grade was determined using the
criteria of Scott et al., 1997 (14).
Clinical, tumor, and treatment features
The age at diagnosis, menopausal status, tumor size,
primary surgical treatment, and adjuvant therapy were
retrospectively evaluated.
Menopausal status was defined based upon in-person
interview data.
Immunohistochemistry
Estrogen receptor (ER), HER2 overexpression, cytokeratin
5 (CK5), and epidermal growth factor receptor (EGFR) were
assessed. The reactions were performed with automated
equipment (BenchMark XT/LTTM – Ventana, USA) using
the UltraView Universal REF 760–500 DAB kit (Ventana,
USA) according to the manufacturer’s instructions. The
sources and dilutions of the primary antibodies are listed in
Table 1.
Allred’s scoring system was used to evaluate estrogen
receptor status; cases were considered positive when at least
Figure 1 - A) High-grade ductal carcinoma in situ associated with invasive mammary carcinoma positive for estrogen receptor (100x).
Arrows indicate the in situ component. B) High-grade ductal carcinoma in situ positive for HER2 (400x). C) High-grade ductal carcinoma
in situ positive for cytokeratin 5 (100x). D) High-grade ductal carcinoma in situ positive for epidermal growth factor receptor (400x).
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1% of neoplastic cells showed moderate or strong nuclear
staining (15). HER2 overexpression was analyzed according
to the American Society of Clinical Oncology and College of
American Pathologists (16). Any degree of cytoplasmic
staining for CK5 and any degree of distinct membranous
staining for EGFR were considered positive expression (17).
Immunohistochemical profile
The tumors were divided into five subgroups according
to their immunohistochemical profile: luminal A (ER+/
HER2-), luminal B (ER+/HER2+), HER2 (ER-/HER2+),
basal-like (ER-/HER2-/EGFR+ and/or CK5+), and ‘‘not
classified’’ (all markers negative) (17,18). The basal-like
phenotype was defined according to Nielsen’s criteria (6).
Statistical analysis
Pearson’s asymptotic and exact chi-square tests were used
to compare proportions. The Mann-Whitney test was used
to compare medians. A p-value,0.05 was considered
statistically significant. The kappa test was used to assess
the concordance between phenotypes. Kappa values greater
than 0.80 demonstrated excellent agreement (19). This study
was approved by the Research Ethics Committee of the
Federal University of Minas Gerais (protocol 655/08).
& RESULTS
Pure DCIS was detected in 46/131 cases (35% of the total),
and 85/131 cases (65% of the total) were DCIS associated
with invasive carcinoma. Immunohistochemistry was per-
formed for 121 cases, including 42 cases of pure DCIS (35%
of the total) and 79 cases of DCIS associated with invasive
carcinoma (65% of the total).
The median age at diagnosis was 51 years (standard
deviation ¡14 years) among cases of pure DCIS and 53
years (standard deviation ¡19 years) among cases of IMC-
associated DCIS (p= 0.913). The median DCIS size was
13 mm. There was no significant difference in menopausal
status (p= 0.779) or median tumor size (p=0.836) between
pure and IMC-associated DCIS cases. There was a sig-
nificant difference in primary surgical treatment and
adjuvant therapy between pure and IMC-associated DCIS
cases (p,0.05). Cases with DCIS associated with IMC were
treated with more extensive surgery and more often
received adjuvant therapy.
The frequencies of the molecular immunophenotypes of
DCIS are shown in Table 2 and Figure 1. Among samples of
pure DCIS, the luminal A phenotype was the most common
(24/42 cases; 57.1%), followed by the HER2 phenotype (07/
42 cases; 16.7%), the ‘‘not classified’’ phenotype (06/42
cases; 14.3%), and the luminal B phenotype (5/42 cases;
11.9%). The basal-like phenotype was not identified among
the pure DCIS cases. The immunophenotypes of DCIS
associated with invasive carcinoma were the following:
luminal A (46/79 cases; 58.2%), luminal B (10/79 cases;
12.7%), HER2 (06/79 cases; 7.6%), basal-like (06/79 cases;
7.6%), and ‘‘not classified’’ (11/79 cases; 13.9%).
There was no significant difference in frequency between
immunophenotypes in pure and IMC-associated DCIS
samples (p.0.05). Excellent agreement was observed
between in situ and invasive components with regard to
immunophenotypes (kappa= 0.867).
& DISCUSSION
Breast cancer comprises a heterogeneous group of
diseases with regard to presentation, morphology, biologi-
cal characteristics, clinical behavior, and response to therapy
(6,9,20). In the past 20 years, concomitant with the wide use
of screening mammography, the DCIS incidence has risen
dramatically (21–22). The understanding of the biology and
clinical behavior of DCIS is currently limited. Molecular
profiling through gene array studies is likely to have a major
impact on breast cancer classification and management, and
it is important that similar approaches are taken to advance
the understanding of DCIS.
The immunohistochemical staining of paraffin sections
using antibody panels has been shown to be a reliable
surrogate for the molecular classification of invasive breast
cancers through gene expression profiling studies.
Antibodies against estrogen receptor, progesterone receptor,
HER2, cytokeratin 5/6, and EGFR have been particularly
useful for this purpose (4–8). In fact, this approach to
molecular classification (that is, using immunostaining as a
surrogate for expression profiling) is arguably the most
practical approach to phenotyping a large number of
archived specimens for which fresh tissue is not available
for expression array analysis.
Recent advances have led to an emerging molecular
classification for invasive breast cancer based on the
biological characteristics of the tumor rather than being
limited to morphological analysis. Much less attention has
been focused on dissecting the biological subtypes of DCIS,
the immediate precursor to invasive breast cancer. There
have been discrepancies in the results of those studies.
There have also been discrepancies in the relative frequency
of subtypes between in situ and invasive disease (17,20,23–
26).
In our series, we showed that DCIS can be classified into
the five immunophenotypes that have been described for
Table 2 - Immunohistochemical profile of high-grade
DCIS (pure or associated with invasive mammary
carcinoma).
Pure DCIS DCIS + IMC
Phenotype N (%) N (%) p-value*
Luminal A 24 (57.1%) 46 (58.2%) 0.264
Luminal B 05 (11.9%) 10 (12.7%)
HER2 07 (16.7%) 06 (7.6%)
Basal-like 00 (0%) 06 (7.6%)
‘‘Not classified’’ 06 (14.3%) 11 (13.9%)
TOTAL 42 (100%) 79 (100%)
DCIS =ductal carcinoma in situ; IMC= invasive mammary carcinoma
Luminal A: ER+/HER2-; Luminal B: ER+/HER2+; HER2: ER-/HER2+; Basal: ER-/
HER2-/EGFR+ and/or CK5+; ‘‘Not classified’’: ER-/HER2-/EGFR-/CK5-.
p= significance level.
* = Exact Pearson’s chi-square test; refers to in situ component (pure or
associated with invasive carcinoma).
Table 1 - Sources and dilutions of the primary antibodies.
Antibody Clone Dilution Manufacturer, Country
ER SP1 Ready to use DAKO, USA
HER2 CB11 1/1000 NovoCastra, UK
CK5 XM26 1/50 NeomarKers, USA
EGFR 31G7 1/25 Zymed, USA
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invasive breast carcinomas using a panel of four markers.
Molecular classification improves the current morphological
classification and provides insight into the biology under-
lying DCIS heterogeneity.
Previous studies have evaluated the immunoprofiles of
DCIS independently of histological grade (17,20,23). Bryan
et al. restricted their study to high-nuclear-grade DCIS
lesions because basal-like invasive carcinomas are poorly
differentiated tumors in histopathological studies (24). In
our study, we chose a specific subset of high-grade DCIS of
the breast to determine the frequency of the basal-like
phenotype because this subtype is more frequent among
invasive tumors that have a high histological grade (9–
11,24).
Basal-like tumors have attracted the attention of pathol-
ogists, surgeons, and oncologists and constitute a prognostic
group of breast cancers with aggressive behavior. These
tumors affect younger patients, are more prevalent in
African-American women, and exist more often as interval
cancers (18). Basal-like tumors are candidates for specific
targeted therapy. By identifying basal-like DCIS, surgeons
and oncologists can likely treat these tumors more aggres-
sively to improve the prognosis.
There is no consensus regarding markers that define
basal-like tumors by immunohistochemistry (11). Some
groups have suggested that basal-like tumors are triple
negative, i.e., negative for estrogen and progesterone
receptors and HER2. However, the triple-negative pheno-
type is not synonymous with the basal-like phenotype
(9,27). Other authors consider the basal-like phenotype as
showing positivity for basal cytokeratins, regardless of the
expression of other markers (5). EGFR positivity, which is
associated with positivity for basal cytokeratins and
negativity for estrogen receptor and HER2, defines basal-
like breast cancers for other authors (6,17–18). EGFR gene
amplification and/or high EGFR expression are biological
predictors of poor prognosis in breast carcinomas. EGFR has
also been used as a marker of the basal phenotype and has
been investigated as a potential target therapy for human
breast cancer (17–18). In our study, we classified the basal-
like phenotype according to Nielsen’s criteria (6), which
includes EGFR evaluation.
Our data demonstrated good agreement between the
molecular profile of DCIS and synchronous IMC with regard
to immunohistochemical phenotypes. Contemporary models
suggest that high- and low-grade invasive ductal cancers
arise through disparate pathways: high-grade IMC develops
directly from poorly differentiated DCIS rather than low-
grade IMC or low-grade DCIS. DCIS represents a stage in the
development of breast cancer in which most molecular
alterations are already present [12,28). Based on this model,
basal-like invasive ductal carcinomas, which are primarily
high grade, arise from high-grade DCIS. Until recently,
however, a basal-like in situ component was not known to
exist.
Livasy et al., Paredes et al., Bryan et al., and Clark et al.
observed the following frequencies of the basal phenotype
in pure DCIS: 8%, 10.1%, 6%, and 4.2%, respectively (17,23–
24,26). In our study, the basal-like phenotype was not
identified among pure DCIS. We identified the basal
phenotype in 7.6% of IMC-associated DCIS cases. Tamimi
et al. observed a similar frequency (7.7%) of the basal
phenotype for the in situ component (20). This difference in
frequencies might be related to the criteria used to classify
tumors as well as variables from the preanalytical and
analytical phases of immunohistochemical reactions, such
as the choice of primary antibodies. According to the tumor
type-specific evolution from DCIS to invasive carcinoma
(28), another possible interpretation of these differences in
frequencies is that the DCIS lesions in the cited papers were
diagnosed at different stages of progression.
Our data showed an increased frequency of the HER2
phenotype in pure high-grade DCIS, which is consistent
with previous studies demonstrating a higher prevalence of
HER2 protein overexpression and gene amplification
among DCIS in comparison to invasive breast cancers and
suggesting that HER2/neu gene amplification is inversely
related to invasive progression in DCIS patients (28–29).
We did not observe a significant difference in the frequencies
of molecular phenotypes in pure or IMC-associated DCIS.
Tamimi et al. showed differences in the frequencies of luminal
A, luminal B, and HER2 phenotypes in pure DCIS versus
invasive breast cancers, but there was no difference in the
basal-like phenotype and ‘‘not classified’’ cases (20).
We did not observe the basal-like phenotype in pure
DCIS, despite the presence of this profile in IMC-associated
DCIS cases. Based on the tumor type-dependent model of
breast cancer progression from DCIS to invasive cancer,
triple-negative cancers may progress much faster than the
other three tumor types, suggesting that some unrecognized
mechanisms or features might help these tumors progress.
At the time of breast tumor diagnosis, more aggressive
types will have fewer DCIS lesions in comparison to the less
aggressive types, with more tumors still in the DCIS phase.
With regard to the speed of becoming invasive breast
cancers, the fastest are the triple-negative lesions, while
pure HER2-positive tumors are almost three times slower.
Luminal A and luminal B DCIS are two tumor types that
show intermediate probabilities of progression to invasive
carcinoma (28). Therefore, our results are in agreement with
the tumor type-dependent model of breast cancer progres-
sion from DCIS to invasive cancer.
In conclusion, immunophenotypes that were previously
identified among invasive mammary carcinomas were also
observed among cases of DCIS. The most common
immunophenotype of pure DCIS was luminal A, followed
by the HER2 phenotype. The basal-like phenotype was
observed only in DCIS associated with invasive carcinoma,
which had a similar phenotype. No significant difference
was identified between pure DCIS and IMC-associated
DCIS phenotypes. There is a critical need for prospective
analyses of new and known breast cancer molecular
markers in large cohorts of patients with DCIS to differ-
entiate indolent from aggressive DCIS and better tailor the
need and extent of current therapies.
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